| 【Company Research】Topsports (6110 HK) - Prudent guidance but strong cash flow & yield |
| 【Company Research】Baozun (BZUN US) - Quality revenue growth on track |
| 【Company Research】Xiaomi (1810 HK) - Key takeaways from product launch event: Self-developed 3nm SoC debut is the bright spot |
| 【Company Research】Kanzhun Limited (BZ US) - Hiring demand remains resilient; full-year earnings target unchanged |
| 【Company Research】iQIYI (IQ US) - Inline 1Q25 results; stepped-up content & marketing investment impacts ST margin |
| 【Company Research】Baidu (BIDU US) - Cloud revenue a strong beat; driving for more aggressive product innovation for search |
| 【Company Research】Palo Alto Networks (PANW US) - AI-related ARR continues ramping up |
| 【Company Research】Xpeng Inc. (XPEV US/9868 HK) - Entered a virtuous circle |
| 【Company Research】Weibo (WB US) - Flattish 1Q25 topline; leverage AI to capture new opportunities |
| 【公司研究】三生制药 (1530 HK) - 与辉瑞达成重磅授权交易，释放PD-1/VEGF的同类最佳潜力 |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
